<DOC>
	<DOCNO>NCT02605967</DOCNO>
	<brief_summary>The purpose randomize controlled Phase II study ass efficacy PDR001 versus investigator 's choice chemotherapy patient advance NPC . By block interaction PD-1 ligands PD-L1 PD-L2 , PDR001 lead activation T cell mediate antitumor immune response</brief_summary>
	<brief_title>Safety Efficacy Study PDR001 Patients With Recurrent Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Histologically document nonkeratinizing locally advanced recurrent metastatic NPC . Must resistant platinumbased chemotherapy ( define progression platinumbased chemotherapy give recurrent/metastatic setting ) . May receive least 1 prior therapy recurrent metastatic disease , 2 prior systemic therapy . An archival tumor specimen newly obtain tumor sample may submit screening/baseline ( fresh tumor sample prefer ) , unless agree differently Novartis Investigator . At least 1 measurable lesion ( per RECIST v1.1 ) progress new since last antitumor therapy . Prior treat brain meningeal metastasis must without MRI evidence progression least 8 week systemic steroid least 2 week prior screening/baseline . Patient must willing undergo test human immunodeficiency virus ( HIV ) test within past 6 month . If HIV+ positive , patient eligible : his/ CD4+ count ≥ 300/μL ; his/her viral load undetectable ; he/she currently receive highly active antiretroviral therapy ( HAART ) . History severe hypersensitivity reaction mAbs Active autoimmune disease document history autoimmune disease , except vitiligo resolve asthma/atopy treated bronchodilator . Active HBV HCV infection require therapy . Prior PD1 PDL1directed therapy therapeutic cancer vaccine . Patients receive systemic treatment immunosuppressive medication . Use vaccines infectious disease ( e.g . varicella , pneumococcus ) within 4 week initiation study treatment . Other protocoldefine inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001 ,</keyword>
	<keyword>nasopharyngeal cancer ,</keyword>
	<keyword>moderately differentiated/undifferentiated ,</keyword>
	<keyword>locally advanced ,</keyword>
	<keyword>recurrent metastatic NPC ,</keyword>
	<keyword>first- line platinum-based therapy</keyword>
</DOC>